Join us for the 2024 Judy Dunn International Conference, ‘Advancing ADHD Care: Evidence-Based Approaches in Child and Adolescent Mental Health’. Don’t miss this opportunity to stay at the forefront of ADHD care. Register now to secure your spot in this invaluable professional development experience.
Booking
Sign up at this link or on the Book Now button at the top of the screen, and complete the form that follows. You’ll then receive an email confirmation and a link to the webinar, plus we’ll send you a calendar reminder nearer the time. Delegates will have exclusive access to recordings for 90 days after the event, together with slides. Plus you will get a personalised CPD certificate via email.
- ACAMH Members MUST login to book onto the webinar in order to access this webinar and get a CPD certificate
- Non-members this is a great time to join ACAMH, take a look at what we have to offer, and make the saving on these sessions
EARLY BIRD
ACAMH Members £99
Non Members £139 Join now and save
£5 Undergraduate / Postgraduate Members
FREE for ACAMH Low and Middle Income Countries Members
Don’t forget as a charity any surplus made is reinvested back as we work to our vision of ‘Sharing best evidence, improving practice’, and our mission to ‘Improve the mental health and wellbeing of young people aged 0-25’.
About the day
- Gain valuable insights into the latest research on ADHD causes, with a special focus on genetic factors. Clinicians will learn how to apply this knowledge to improve patient care and treatment planning.
- Explore current best practices in ADHD diagnosis, including new assessment tools and techniques. This session will provide practical guidance for conducting thorough and accurate evaluations.
- Discover evidence-based non-pharmacological treatments for ADHD, including behavioural therapies, cognitive training, and lifestyle modifications. Learn how to integrate these approaches into comprehensive treatment plans.
- Review the latest research on ADHD medications, their efficacy, and safety profiles. Our experts will discuss how to optimise pharmacological interventions based on individual patient needs.
- Examine the concept of neurodiversity and its implications for mental health conditions. Our speakers will delve into the benefits and challenges of incorporating neurodiversity perspectives into clinical work with children and adolescents.
Why attend?
- Gain practical knowledge from leading researchers and clinicians
- Learn about the latest evidence-based interventions for ADHD
- Enhance your diagnostic and treatment skills
- Explore neurodiversity and mental health
Who should attend
This is essential for mental health professionals, educators, and researchers working with children and adolescents with ADHD.
About the talks
Professor Anita Thapar – ADHD: Transition to severe mental illness
Most with ADHD do not develop a severe mental disorder (SMD) such as psychosis or bipolar disorder. However, some do, and studies have shown that ADHD is associated with increased rates of multiple different types of mental health conditions. This includes a 4 to 8 times increased risk of bipolar disorder and psychosis. In this talk I consider what are the different potential explanations for the transition to SMD, and whether we have evidence on how best clinicians should manage the combination of conditions.
Learning outcomes
- Understand the increased risk for different mental health disorders in people with ADHD.
- Understand potential explanations as to why ADHD maybe associated with severe mental illness.
- To recognise who is at highest risk and how to treat ADHD/SMD comorbidity.
Dr. Giorgia Michelini – Understanding ADHD and mental health outcomes through a neurodiversity lens
ADHD is currently classified as a neurodevelopmental disorder (NDD) in diagnostic manuals. While most research on NDDs has followed a medical model, the neurodiversity framework encourages us to view ADHD and other NDDs as expressions of variation in minds and cognitive abilities, rather than as disorders. This perspective also shifts research efforts toward improving the lives of neurodiverse individuals, particularly by enhancing mental health outcomes. Children and young people with ADHD experience higher rates of mental health challenges, such as anxiety and depression, compared to their neurotypical peers. However, the drivers of these co-occurring challenges remain poorly understood. In this talk, I will provide an overview of the neurodiversity framework and discuss how it can inform our understanding of ADHD and related mental health outcomes.
Learning outcomes
- To understand current conceptualisations of ADHD.
- To understand how the neurodiversity framework can be applied to ADHD.
- To understand how the neurodiversity framework can further our understanding of mental health outcomes.
Dr. Charlotte Hall – Supporting ADHD assessment for children and young people using a computerised assessment tool (QbTest)
NICE have recently recommending the use of QbTest to support usual clinical practice in the assessment of ADHD in children and young people. QbTest is a commercial tool provided by Qbtech Ltd. that measures the core symptoms of ADHD (attention, impulsivity and hyperactivity) and produces a report which compares the individuals performance to a normed sample. The report can be used to supplement other sources of information (e.g. questionnaires, interviews) to inform the clinician’s diagnostic decision and be discussed with the family and young person. QbTest is currently being used widely across many NHS Trusts in England. This talk explores the key evidence underpinning QbTest to help listeners understand why NICE have recommended its use. The talk discusses the key strengths and limitations to QbTest and reflects on points to consider when integrating QbTest in clinical practice.
Learning outcomes
- To understand the strengths and limitations of QbTest
- To understand the key evidence underpinning QbTest
- To understand why NICE have recommended QbTest to support ADHD assessment
Prof. Luis Rohde – What clinicians should know about ADHD trajectories
ADHD is traditionally conceptualised as a neurodevelopmental disorder implying an onset in infancy or early childhood and a stable course with two main trajectories: persistence from childhood to adulthood or decrease of symptoms and impairment possible related to brain maturation. In this talk, Prof. Luis A. Rohde, a renowned expert in ADHD, will explore recent new data challenging these key notions about ADHD trajectory, as well as explore ways of predicting ADHD persistence from childhood to adulthood bring the disorder to the context of personalised medicine. Thus, this session is ideal for clinicians, social workers, educators, and patients seeking to enhance their knowledge and skills on trajectories of ADHD.
Learning outcomes
1. To understand modern concepts on ADHD trajectories
Prof. Samuele Cortese – Pharmacological treatment evidence base informing clinical practice
I will provide an update on the research on the pharmacological treatment of ADHD, highlighting how research findings can inform social practice and the different steps involved in the prescription and follow-up of ADHD medications.
Learning outcomes
- Know the evidence base on the comparative efficacy and tolerability of ADHD medications.
- Appreciate the importance of dose optimization.
- Understand how to manage side effects.
Prof. David Daley – Non pharmacological treatments for ADHD
In this brief talk we will first of all establish the rational for non-pharmacological interventions for ADHD, focusing quickly on behavioural interventions which are the most evidence based and recommended type of non-pharmacological intervention. Then focusing on high quality meta-analyses, individual participant data meta analyses and , key practitioner reviews the evidence for behavioural interventions overall, as well as key aspects of the evidence base will be explored.
Learning outcomes
- To understand what non-pharmacological interventions can offer for families of children with ADHD
- To gain a better understanding of which families might benefit the most
- To gain greater clinical confidence if recommending interventions
Prof. Samuele Cortese – Pharmacological treatment evidence base informing clinical practice
I will provide an update on the research on the pharmacological treatment of ADHD, highlighting how research findings can inform social practice and the different steps involved in the prescription and follow-up of ADHD medications.
Learning outcomes
- Know the evidence base on the comparative efficacy and tolerability of ADHD medications.
- Appreciate the importance of dose optimization.
- Understand how to manage side effects.
Programme (subject to change)
10:15 Welcome and Introduction Prof Sam Cortese (TBC)
10:20 Dr. Giorgia Michelini – Understanding ADHD and mental health outcomes through a neurodiversity lens
10:45 Q&A
10:55 Dr. Giorgia Michelini, Prof. Anita Thapar, Prof. David Coghill, and Prof. Emily Simonoff – Discussion on the concept of neurodiversity
11:35 Break
11:45 Prof. Anita Thapar – ADHD: Transition to severe mental illness
12:10 Q&A
12:20 Dr. Charlotte Hall – Supporting ADHD assessment for children and young people using a computerised assessment tool (QbTest)
12:40 Q&A
12:50 Lunch
13:35 Welcome back Dr. Gordana Milavić, ACAMH Chair
13:40 Prof. Luis Rohde – What clinicians should know about ADHD trajectories
14:10 Q&A
14:20 Prof. David Daley – Non pharmacological treatments for ADHD
14:50 Q&A
15:00 Break
15:10 Prof. Samuele Cortese – Pharmacological treatment evidence base informing clinical practice
15:40 Q&A
15:50 Closing remarks Dr. Gordana Milavić, ACAMH Chair
15:55 End
About the speakers
Professor Samuele Cortese, MD, PhD is currently Professor of Child and Adolescent Psychiatry at the University of Southampton and Honorary Consultant Child and Adolescent Psychiatry for Solent NHS Trust. He is also Adjunct Full Professor with the New York University (NYU). Prof. Cortese’s main research interest are around neurodevelopmental disorders, with a focus on ADHD. In his research, he uses advanced evidence synthesis methods to address clinically relevant questions. He has published more than 350 peer-review papers and secured external funding as main or co-applicant for more than £ 13M. In 2022, Prof. Cortese was included in the list of the world’s most influential researchers of the past decade, demonstrated by the production of multiple highly-cited papers that rank in the top 1% by citations in the field of psychiatry/psychology in 2021 in Web of Science. In 2022, he ranked #1 worldwide in terms of expertise on Attention-Deficit/Hyperactivity Disorder (ADHD) according to Expertscape.
I am a Professor Anita Thapar, a clinician scientist. My primary interests are in child neurodevelopmental disorders and depression. I was Lead Editor (Joint) of the 6th Edition of Rutter’s Child and Adolescent Psychiatry-the leading textbook for clinicians and scientists. I head the academic Child and Adolescent Psychiatry Section in the Division of Psychological Medicine and Clinical Neurosciences and the developmental disorders group within the MRC Centre for Neuropsychiatric Genetics and Genomics and Division. I also have honorary NHS consultant contracts with Cwm Taf and Cardiff and Vale UHBs.
Dr. Giorgia Michelini is a Lecturer (Assistant Professor) in Psychology at Queen Mary University of London and a Visiting Researcher at King’s College London and at the University of California Los Angeles (UCLA). After completing a BSc in Psychology and MSc in Clinical Psychology, she pursued a PhD in Developmental Psychopathology and Neuroscience at King’s College London, supervised by Professor Jonna Kuntsi. Her PhD work was awarded the 2018 Elsevier Outstanding Doctoral Thesis Prize and the 2018 Neil O’Connor Prize from the British Psychological Society. She then completed postdoctoral fellowships in the US at SUNY Stony Brook and UCLA, before returning to the UK to take up her current position. Her research seeks to elucidate the biological and psychosocial processes underlying neurodevelopmental (e.g., ADHD) and affective disorders, as well as their co-occurrence, in order to inform prevention, early identification, and treatment strategies. Her work has been supported by the National Institute of Heath Research, Brain and Behavior Research Foundation (NARSAD) and Klingenstein Third Generation Foundation.
Professor David Daley is a specialist in Psychological Intervention and Behaviour Change at the University of Nottingham. He heads the Children and Young People’s Theme and serves as Head of Applied Psychological Practice at Nottingham Trent University since July 2022. With a background in Applied Psychology, including a Ph.D. in Developmental Psychopathology, he leads the Neurodevelopmental theme at MindTech, a national center for mental healthcare and dementia technology. His research centers on enhancing parenting experiences for Neurodevelopmental Disorder families and environmental modification for ADHD. With over 160 academic papers and two books, he’s currently developing a digital sleep intervention for children with ADHD, collaborating with the Institute of Mental Health’s CANDAL and NIHR MindTech.
Dr. Charlotte Hall is a Principal Research Fellow working within NIHR MindTech-MedTech Cooperative HRC and Biomedical Research Centre at the University of Nottingham. Charlotte has a keen interest in exploring how digital interventions can be used to improve the assessment and treatment of mental health disorders in young people, with a particular focus on neurodevelopmental disorders. She is also interested in how interventions with established clinical and cost-effectiveness may be adopted and evaluated into routine practice. Charlotte was the Trial Manager on the landmark QbTest “AQUA-Trial” published in Journal of Child Psychology and Psychiatry. Charlotte subsequently led the real-world evaluation of the national implementation of QbTest conducted by the Health Innovation Network.
Prof. Luis Rohde is currently Full Professor of Psychiatry at Federal University of Rio Grande do Sul and Professor of the Graduate Program in Psychiatry at the University of São Paulo (USP), Brazil. He is vice coordinator of the Center for Research and Innovation in Mental Health (CISM), an initiative funded. Internationally, he was President of the World Federation of ADHD and participated in the working group to define the diagnostic criteria for ADHD and Disruptive Disorders of the DSM-5 of the American Psychiatric Association. He is the current President of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP). He was Associate Editor of the European Child and Adolescent Psychiatry, International Editor of the Journal of the American Academy of Child and Adolescent Psychiatry, and Associate Editor of Attention Deficit and Hyperactivity Disorders and the Journal of Attention Disorders. He is currently editor emeritus of the Brazilian Journal of Psychiatry. In terms of scientific production, he has published more than 460 scientific articles, 50 book chapters or editorials, and is the organizer or editor of 9 books on the mental health of children and adolescents in Brazil, England, Germany and the USA. It has about 49000 citations per doc and H Index = 90 (Google Scholar). Between 2020 and 2023, he was among the researchers most influential in the fields of psychology and psychiatry (top 1%) for the last decade according to Clarivate (Web of Science).
Professor David Coghill is a child and adolescent psychiatrist with a particular interest in ADHD, disruptive behaviours and psychopharmacology. He leads the Developmental Research Group within the Division of Neuroscience. The Developmental Research Group has a particular interest in fostering a better understanding of the pathophysiology of ADHD, conduct disorder and depression using a broad range of approaches including neuropsychopharmacology, neuroimaging,genetics and pharmacogenomics. The group is also very involved in clinical trials, pharmacoepidemiology, patient reported outcomes and quality of life and works hard to facilitate a rapid translation of research evidence into routine clinical practice. The group’s research is funded through a range of sources including the European Union, NIHR and Industry and include international collaborations across Europe, North America and Asia.
Booking
Sign up at this link or on the Book Now button at the top of the screen, and complete the form that follows. You’ll then receive an email confirmation and a link to the webinar, plus we’ll send you a calendar reminder nearer the time. Delegates will have exclusive access to recordings for 90 days after the event, together with slides. Plus you will get a personalised CPD certificate via email.
- ACAMH Members MUST login to book onto the webinar in order to access this webinar and get a CPD certificate
- Non-members this is a great time to join ACAMH, take a look at what we have to offer, and make the saving on these sessions
EARLY BIRD
ACAMH Members £119
Non Members £139 Join now and save
£5 Undergraduate / Postgraduate Members
FREE for ACAMH Low and Middle Income Countries Members
Don’t forget as a charity any surplus made is reinvested back as we work to our vision of ‘Sharing best evidence, improving practice’, and our mission to ‘Improve the mental health and wellbeing of young people aged 0-25’.